文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

纽约州COVID-19住院患者接受羟氯喹或阿奇霉素治疗与院内死亡率的关联

Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.
PubMed 文献 · JAMA · 2020-01-01
一句话结论纽约大都会区1438例COVID-19住院患者的回顾性多中心队列显示,羟氯喹联合或不联合阿奇霉素、或单用阿奇霉素,与未用两药者相比院内死亡率无显著差异;羟氯喹联合阿奇霉素组心脏骤停风险显著更高(校正OR 2.13)。

该研究为回顾性多中心队列,纳入纽约大都会区25家医院2020年3月15日至28日住院≥24小时的实验室确诊COVID-19患者1438例(男性59.7%,中位年龄63岁),随访截止2020年4月24日。总体院内死亡率为20.3%(95%CI 18.2%-22.4%)。与两药均未使用组相比,羟氯喹联合阿奇霉素组(HR 1.35,95%CI 0.76-2.40)、单用羟氯喹组(HR 1.08,95%CI 0.63-1.85)、单用阿奇霉素组(HR 0.56,95%CI 0.26-1.21)的院内死亡率均无显著差异。羟氯喹联合阿奇霉素组心脏骤停风险显著高于未用两药组(校正OR 2.13,95%CI 1.12-4.05),单用羟氯喹(校正OR 1.91,95%CI 0.96-3.81)和单用阿奇霉素(校正OR 0.64,95%CI 0.27-1.56)无显著差异;异常心电图表现(心律失常或QT延长)的相对风险无显著差异。作者结论认为,在纽约大都会区COVID-19住院患者中,羟氯喹、阿奇霉素或两药联合与未用两药相比,院内死亡率无显著差异,但观察性设计可能限制对这些发现的解释。

要点

  • 在1438例COVID-19住院患者中,羟氯喹联合阿奇霉素组院内死亡率25.7%(189/735),单用羟氯喹组19.9%(54/271),单用阿奇霉素组10.0%(21/211),两药均未用组12.7%(28/221)。
  • 校正Cox模型显示,与两药均未用组相比,羟氯喹联合阿奇霉素(HR 1.35,95%CI 0.76-2.40)、单用羟氯喹(HR 1.08,95%CI 0.63-1.85)、单用阿奇霉素(HR 0.56,95%CI 0.26-1.21)的院内死亡率均无显著差异。
  • 羟氯喹联合阿奇霉素组心脏骤停风险显著高于两药均未用组(校正OR 2.13,95%CI 1.12-4.05),单用羟氯喹(校正OR 1.91,95%CI 0.96-3.81)和单用阿奇霉素(校正OR 0.64,95%CI 0.27-1.56)无显著差异。
  • 异常心电图表现(心律失常或QT延长)在各用药组与两药均未用组之间的相对风险无显著差异。
  • 作者结论认为,羟氯喹、阿奇霉素或两药联合与未用两药相比,院内死亡率无显著差异,但观察性设计可能限制对这些发现的解释。

适用人群与场景

  • 纽约大都会区25家医院中随机抽样的实验室确诊COVID-19住院患者,代表该地区88.2%的COVID-19患者。
  • 纳入标准为2020年3月15日至28日期间住院至少24小时。
  • 最终随访日期为2020年4月24日。

研究设计与关键结果

  • 研究类型:回顾性多中心队列研究,纳入25家医院1438例实验室确诊COVID-19住院患者(男性858例[59.7%],中位年龄63岁)。
  • 暴露分组:羟氯喹联合阿奇霉素、单用羟氯喹、单用阿奇霉素、两药均未用。
  • 总体院内死亡率为20.3%(95%CI 18.2%-22.4%);各组死亡率:羟氯喹联合阿奇霉素25.7%(189/735,95%CI 22.3%-28.9%),单用羟氯喹19.9%(54/271,95%CI 15.2%-24.7%),单用阿奇霉素10.0%(21/211,95%CI 5.9%-14.0%),两药均未用12.7%(28/221,95%CI 8.3%-17.1%)。
  • 校正Cox比例风险模型:与两药均未用组相比,羟氯喹联合阿奇霉素组HR 1.35(95%CI 0.76-2.40),单用羟氯喹组HR 1.08(95%CI 0.63-1.85),单用阿奇霉素组HR 0.56(95%CI 0.26-1.21),均无显著差异。
  • 校正Logistic模型:与两药均未用组相比,羟氯喹联合阿奇霉素组心脏骤停风险显著更高(校正OR 2.13,95%CI 1.12-4.05);单用羟氯喹组(校正OR 1.91,95%CI 0.96-3.81)和单用阿奇霉素组(校正OR 0.64,95%CI 0.27-1.56)无显著差异。
  • 异常心电图表现(心律失常或QT延长)在各组间的相对风险无显著差异。
  • 与两药均未用组相比,接受羟氯喹、阿奇霉素或两药联合者更可能合并糖尿病、呼吸频率>22/min、胸部影像异常、氧饱和度低于90%及天冬氨酸氨基转移酶大于40 U/L。

证据类型、等级与局限

  • 证据类型:回顾性多中心队列研究。
  • 局限:原文自述观察性设计可能限制对这些发现的解释。

对床旁实践的改变

  • 该研究提示,在纽约大都会区COVID-19住院患者中,羟氯喹联合或不联合阿奇霉素、或单用阿奇霉素与未用两药相比,院内死亡率无显著差异,但观察性设计可能限制对这些发现的解释。

指南或共识出处

  • JAMA

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Hydroxychloroquine, with or without azithromycin, has been considered as a possible therapeutic agent for patients with coronavirus disease 2019 (COVID-19). However, there are limited data on efficacy and associated adverse events.

OBJECTIVE: To describe the association between use of hydroxychloroquine, with or without azithromycin, and clinical outcomes among hospital inpatients diagnosed with COVID-19.

DESIGN, SETTING, AND PARTICIPANTS: Retrospective multicenter cohort study of patients from a random sample of all admitted patients with laboratory-confirmed COVID-19 in 25 hospitals, representing 88.2% of patients with COVID-19 in the New York metropolitan region. Eligible patients were admitted for at least 24 hours between March 15 and 28, 2020. Medications, preexisting conditions, clinical measures on admission, outcomes, and adverse events were abstracted from medical records. The date of final follow-up was April 24, 2020.

EXPOSURES: Receipt of both hydroxychloroquine and azithromycin, hydroxychloroquine alone, azithromycin alone, or neither.

MAIN OUTCOMES AND MEASURES: Primary outcome was in-hospital mortality. Secondary outcomes were cardiac arrest and abnormal electrocardiogram findings (arrhythmia or QT prolongation).

RESULTS: Among 1438 hospitalized patients with a diagnosis of COVID-19 (858 [59.7%] male, median age, 63 years), those receiving hydroxychloroquine, azithromycin, or both were more likely than those not receiving either drug to have diabetes, respiratory rate >22/min, abnormal chest imaging findings, O2 saturation lower than 90%, and aspartate aminotransferase greater than 40 U/L. Overall in-hospital mortality was 20.3% (95% CI, 18.2%-22.4%). The probability of death for patients receiving hydroxychloroquine + azithromycin was 189/735 (25.7% [95% CI, 22.3%-28.9%]), hydroxychloroquine alone, 54/271 (19.9% [95% CI, 15.2%-24.7%]), azithromycin alone, 21/211 (10.0% [95% CI, 5.9%-14.0%]), and neither drug, 28/221 (12.7% [95% CI, 8.3%-17.1%]). In adjusted Cox proportional hazards models, compared with patients receiving neither drug, there were no significant differences in mortality for patients receiving hydroxychloroquine + azithromycin (HR, 1.35 [95% CI, 0.76-2.40]), hydroxychloroquine alone (HR, 1.08 [95% CI, 0.63-1.85]), or azithromycin alone (HR, 0.56 [95% CI, 0.26-1.21]). In logistic models, compared with patients receiving neither drug cardiac arrest was significantly more likely in patients receiving hydroxychloroquine + azithromycin (adjusted OR, 2.13 [95% CI, 1.12-4.05]), but not hydroxychloroquine alone (adjusted OR, 1.91 [95% CI, 0.96-3.81]) or azithromycin alone (adjusted OR, 0.64 [95% CI, 0.27-1.56]), . In adjusted logistic regression models, there were no significant differences in the relative likelihood of abnormal electrocardiogram findings.

CONCLUSIONS AND RELEVANCE: Among patients hospitalized in metropolitan New York with COVID-19, treatment with hydroxychloroquine, azithromycin, or both, compared with neither treatment, was not significantly associated with differences in in-hospital mortality. However, the interpretation of these findings may be limited by the observational design.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA. 2020. PMID: 32392282. doi:10.1001/jama.2020.8630

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。